C
2.55
0.07 (2.82%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Chemomab Therapeutics Ltd. | 混合的 | 看涨 |
AIStockmoo 评分
0.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.5 |
| 平均 | 0.17 |
|
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 15.27% |
| 机构持股比例 | 16.93% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Adar1 Capital Management, Llc | 30 Jun 2026 | 80,000 |
| Kestra Private Wealth Services, Llc | 30 Jun 2026 | 61,710 |
| Ikarian Capital, Llc | 30 Jun 2026 | 51,793 |
| Philadelphia Investment Partners, Llc | 30 Jun 2026 | 15,000 |
| Lido Advisors, Llc | 30 Jun 2026 | 14,341 |
| Gamma Investing Llc | 30 Jun 2026 | 4,740 |
| Smartharvest Portfolios, Llc | 30 Jun 2026 | 0 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合